[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003020311A1 - Remedies for skin diseases - Google Patents

Remedies for skin diseases Download PDF

Info

Publication number
WO2003020311A1
WO2003020311A1 PCT/JP2002/008235 JP0208235W WO03020311A1 WO 2003020311 A1 WO2003020311 A1 WO 2003020311A1 JP 0208235 W JP0208235 W JP 0208235W WO 03020311 A1 WO03020311 A1 WO 03020311A1
Authority
WO
WIPO (PCT)
Prior art keywords
testosterone
remedies
reductase inhibitor
skin diseases
effect
Prior art date
Application number
PCT/JP2002/008235
Other languages
French (fr)
Japanese (ja)
Inventor
Shozo Sakuma
Yoshihiro Yokota
Shinichi Kishi
Hiroko Takeuchi
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of WO2003020311A1 publication Critical patent/WO2003020311A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It is confirmed that a testosterone 5α-reductase inhibitor has an effect of inhibiting the proliferation of keratinocytes and, further, inhibits inflammatory responses and epidermal thickening in various animal models pathologically resembling to psoriasis. Namely, it is found out that the testosterone 5α-reductase inhibitor has a keratinocyte proliferation inhibitory effect as well as an antiinflammatory effect. Thus, remedies for skin diseases containing the testosterone 5α-reductase inhibitor as the active ingredient are provided.
PCT/JP2002/008235 2001-08-28 2002-08-12 Remedies for skin diseases WO2003020311A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001257554 2001-08-28
JP2001-257554 2001-08-28

Publications (1)

Publication Number Publication Date
WO2003020311A1 true WO2003020311A1 (en) 2003-03-13

Family

ID=19085194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008235 WO2003020311A1 (en) 2001-08-28 2002-08-12 Remedies for skin diseases

Country Status (1)

Country Link
WO (1) WO2003020311A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155096A2 (en) * 1984-02-27 1985-09-18 Merck & Co. Inc. 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors
EP0291245A2 (en) * 1987-05-11 1988-11-17 Ono Pharmaceutical Co., Ltd. Benzoylaminophenoxybutanoic acid derivatives
EP0458207A2 (en) * 1990-05-21 1991-11-27 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
EP0519353A2 (en) * 1991-06-17 1992-12-23 Fujisawa Pharmaceutical Co., Ltd. Indolizin derivatives, process for their preparation and pharmaceutical composition containing them
EP0715852A1 (en) * 1994-12-05 1996-06-12 Denki Kagaku Kogyo Kabushiki Kaisha Use of hyaluronic acid or its salt to treat skin disease
WO2000006144A1 (en) * 1998-07-27 2000-02-10 Howard Murad Pharmaceutical compositions and methods for managing scalp conditions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155096A2 (en) * 1984-02-27 1985-09-18 Merck & Co. Inc. 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors
EP0291245A2 (en) * 1987-05-11 1988-11-17 Ono Pharmaceutical Co., Ltd. Benzoylaminophenoxybutanoic acid derivatives
EP0458207A2 (en) * 1990-05-21 1991-11-27 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
EP0519353A2 (en) * 1991-06-17 1992-12-23 Fujisawa Pharmaceutical Co., Ltd. Indolizin derivatives, process for their preparation and pharmaceutical composition containing them
EP0715852A1 (en) * 1994-12-05 1996-06-12 Denki Kagaku Kogyo Kabushiki Kaisha Use of hyaluronic acid or its salt to treat skin disease
WO2000006144A1 (en) * 1998-07-27 2000-02-10 Howard Murad Pharmaceutical compositions and methods for managing scalp conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAZZARO-PORRO M. ET AL.: "L'acido azelaico nella terapia dell'acne", GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, vol. 124, no. 4, 1989, pages 175 - 184, XP002959852 *
PASSI S. ET AL.: "Meccanismo di azione dell'acido azelaico nell'acne", GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, vol. 124, no. 10, 1989, pages 455 - 463, XP002081116 *

Similar Documents

Publication Publication Date Title
AU2002258066A1 (en) Dermatological and cosmetic compositions
AU6720300A (en) Compositions comprising conjugated linoleic acid (cla)
WO2003051294A3 (en) Mitocidal compositions and methods
DE60329180D1 (en) SEBUM- AND WELD-ABSORBING FOUNDATION SET AND CORRESPONDING MULTI-STAGE PROCESS
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
ATE296612T1 (en) ACTIVE INGREDIENTS FOR THE TREATMENT OF SENIL XEROSIS AND PREPARATIONS
WO2006040688A3 (en) Inhibitors of acetylcholinesterase for treating skin diseases
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
AU3227700A (en) Skin sanitizing compositions
WO2004047792A3 (en) Liposomal glucocorticoids
AU2003206690A1 (en) Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides
AUPQ877300A0 (en) Topical treatment of skin
EP1319402A4 (en) INHIBITORS OF IgE PRODUCTION
AU2001286562A1 (en) Use of agaricus blazei murill to prevent or treat skin and other disorders
WO2003077856A3 (en) Lotion compositions
TW200602031A (en) Antiinflammatory and pain-relieving agent for external, use
WO2004007475A8 (en) Flavonoid compounds as therapeutic antioxidants
WO2002089799A3 (en) Use of dihydropyrazoles to increase erythropoietin and vasculari zation
AU2002229644A1 (en) Cosmetic compositions for preventing skin irritation
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2004052275A3 (en) Methods of producing lignin peroxidase and its use in skin and hair lightening
DE50001610D1 (en) ANTIOXIDATIVE SKIN CARE PRODUCTS
WO2005079775A8 (en) Method and preparation for reducing irritation and/or inflammatory reaction in human skin
WO2004087181A3 (en) ACTIVE INGREDIENT COMBINATIONS OF PLANT OILS CONTAINING ω3-FATTY ACIDS AND PLANT EXTRACTS CONTAINING POLYPHENOLS AND THE USE THEREOF
AU2002218161A1 (en) Combinations of active ingredients for protecting animal skins and leather

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP